TSPAN5

Summary

TSPAN5 (tetraspanin 5, HGNC:17753) is a protein-coding gene on chromosome 4q23, encoding Tetraspanin-5 (P62079). Part of TspanC8 subgroup, composed of 6 members that interact with the transmembrane metalloprotease ADAM10.

The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility.

Source: NCBI Gene 10098 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 29 total
• MANE Select transcript: NM_005723

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17753
Approved symbol	TSPAN5
Name	tetraspanin 5
Location	4q23
Locus type	gene with protein product
Status	Approved
Aliases	Tspan-5, NET-4
Ensembl gene	ENSG00000168785
Ensembl biotype	protein_coding
OMIM	613136
Entrez	10098

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 12 protein_coding, 3 nonsense_mediated_decay, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000305798, ENST00000505184, ENST00000507167, ENST00000508798, ENST00000509168, ENST00000511651, ENST00000511753, ENST00000511800, ENST00000515287, ENST00000515440, ENST00000852740, ENST00000852741, ENST00000852742, ENST00000935828, ENST00000935829, ENST00000935830, ENST00000935831, ENST00000951778

RefSeq mRNA: 1 — MANE Select: NM_005723 NM_005723

CCDS: CCDS3646

Canonical transcript exons

ENST00000305798 — 8 exons

Exon	Start	End
ENSE00001232858	98658146	98658611
ENSE00003484879	98476189	98476305
ENSE00003513334	98486738	98486884
ENSE00003546857	98478685	98478810
ENSE00003578154	98476413	98476460
ENSE00003590360	98507678	98507728
ENSE00003647635	98470367	98472587
ENSE00003648638	98482005	98482175

Expression profiles

Bgee: expression breadth ubiquitous, 274 present calls, max score 99.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.7186 / max 447.4683, expressed in 1513 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
53221	21.5488	1512
53219	0.9856	390
53220	0.8526	534
53222	0.1179	50
53218	0.1078	32
53223	0.1058	20

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.10	gold quality
cerebellar vermis	UBERON:0004720	98.67	gold quality
middle temporal gyrus	UBERON:0002771	98.65	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.30	gold quality
ventricular zone	UBERON:0003053	98.11	gold quality
paraflocculus	UBERON:0005351	97.56	gold quality
ganglionic eminence	UBERON:0004023	97.12	gold quality
pons	UBERON:0000988	97.03	gold quality
frontal pole	UBERON:0002795	96.63	gold quality
corpus callosum	UBERON:0002336	96.46	gold quality
oocyte	CL:0000023	96.39	gold quality
cerebellum	UBERON:0002037	96.39	gold quality
cerebellar cortex	UBERON:0002129	96.39	gold quality
cerebellar hemisphere	UBERON:0002245	96.34	gold quality
primary visual cortex	UBERON:0002436	96.33	gold quality
occipital lobe	UBERON:0002021	96.04	gold quality
cortical plate	UBERON:0005343	95.77	gold quality
buccal mucosa cell	CL:0002336	95.76	gold quality
endothelial cell	CL:0000115	95.75	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.64	gold quality
parietal lobe	UBERON:0001872	95.55	gold quality
entorhinal cortex	UBERON:0002728	95.44	gold quality
postcentral gyrus	UBERON:0002581	95.34	gold quality
inferior vagus X ganglion	UBERON:0005363	95.18	gold quality
superior frontal gyrus	UBERON:0002661	95.11	gold quality
prefrontal cortex	UBERON:0000451	94.94	gold quality
stromal cell of endometrium	CL:0002255	94.59	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.36	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.25	gold quality
frontal cortex	UBERON:0001870	94.14	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-10042	yes	27.17
E-CURD-119	yes	22.85
E-MTAB-9221	yes	13.86
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

115 targeting TSPAN5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-4447	99.85	67.81	2900

Literature-anchored findings (GeneRIF, showing 9)

• Tspan5 may serve as a prognostic biomarker for predicting outcome of gastric cancer patients. Tspan5 functions as a tumour suppressor in stomach to control the tumour growth. (PMID:27223087)
• two TspanC8-specific motifs in the large extracellular domain of Tspan5 that are important for ADAM10 interaction and exit from the endoplasmic reticulum. One of the anti-Tspan5 mAbs does not recognize Tspan5 associated with ADAM10, providing a convenient way to measure the fraction of Tspan5 not associated with ADAM10. (PMID:28428248)
• Endothelial Tspan5- and Tspan17-ADAM10 complexes may regulate inflammation by maintaining normal VE-cadherin expression and promoting T lymphocyte transmigration. (PMID:28600292)
• intensity in villi in tubal pregnancy was significantly higher than that in normal intrauterine pregnancy (PMID:29908376)
• TSPAN5 Enriched Microdomains Provide a Platform for Dendritic Spine Maturation through Neuroligin-1 Clustering. (PMID:31665629)
• Data show that gene tetraspanin-5 (TSPAN5) is the target of miR-155 in breast cancer (BC). (PMID:32096299)
• TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. (PMID:32753686)
• Tspan5 promotes epithelial-mesenchymal transition and tumour metastasis of hepatocellular carcinoma by activating Notch signalling. (PMID:33955149)
• The relationship between expression of Tspan5 mRNA in maternal-fetal interface and tubal pregnancy. (PMID:38422804)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tspan5	ENSMUSG00000028152
rattus_norvegicus	Tspan5	ENSRNOG00000015913

Paralogs (32): TSPAN6 (ENSG00000000003), CD9 (ENSG00000010278), TSPAN9 (ENSG00000011105), TSPAN17 (ENSG00000048140), TSPAN32 (ENSG00000064201), CD82 (ENSG00000085117), TSPAN15 (ENSG00000099282), CD37 (ENSG00000104894), UPK1A (ENSG00000105668), TSPAN12 (ENSG00000106025), TSPAN13 (ENSG00000106537), TSPAN14 (ENSG00000108219), CD81 (ENSG00000110651), TSPAN11 (ENSG00000110900), PRPH2 (ENSG00000112619), UPK1B (ENSG00000114638), TSPAN1 (ENSG00000117472), TSPAN8 (ENSG00000127324), TSPAN16 (ENSG00000130167), TSPAN2 (ENSG00000134198), CD63 (ENSG00000135404), TSPAN31 (ENSG00000135452), TSPAN3 (ENSG00000140391), CD53 (ENSG00000143119), ROM1 (ENSG00000149489), TSPAN7 (ENSG00000156298), TSPAN18 (ENSG00000157570), TSPAN33 (ENSG00000158457), CD151 (ENSG00000177697), TSPAN10 (ENSG00000182612), TSPAN4 (ENSG00000214063), TSPAN19 (ENSG00000231738)

Protein

Protein identifiers

Tetraspanin-5 — P62079 (reviewed: P62079)

Alternative names: Tetraspan NET-4, Transmembrane 4 superfamily member 9

All UniProt accessions (7): B7Z317, D6R9N6, D6RAR1, D6RBT5, D6RGZ7, P62079, H0Y8W4

UniProt curated annotations — full annotation on UniProt →

Function. Part of TspanC8 subgroup, composed of 6 members that interact with the transmembrane metalloprotease ADAM10. This interaction is required for ADAM10 exit from the endoplasmic reticulum and for enzymatic maturation and trafficking to the cell surface as well as substrate specificity. Different TspanC8/ADAM10 complexes have distinct substrates. Promotes ADAM10-mediated cleavage of CD44. Seems to regulate VE-cadherin expression in endothelial cells probably through interaction with ADAM10, promoting leukocyte transmigration.

Subunit / interactions. Interacts with ADAM10; the interaction influences ADAM10 substrate specificity, endocytosis and turnover.

Subcellular location. Cell membrane.

Post-translational modifications. Palmitoylated.

Similarity. Belongs to the tetraspanin (TM4SF) family.

RefSeq proteins (1): NP_005714* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000301	Tetraspanin_animals	Family
IPR008952	Tetraspanin_EC2_sf	Homologous_superfamily
IPR018499	Tetraspanin/Peripherin	Family
IPR018503	Tetraspanin_CS	Conserved_site

Pfam: PF00335

UniProt features (19 total): topological domain 5, glycosylation site 4, disulfide bond 4, transmembrane region 4, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P62079-F1	89.48	0.76

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (4): 153–221, 154–186, 170–180, 187–200

Glycosylation sites (4): 49, 169, 174, 232

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-977225	Amyloid fiber formation

MSigDB gene sets: 260 (showing top): TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_POSITIVE_REGULATION_OF_NOTCH_SIGNALING_PATHWAY, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, CEBPB_01, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GNF2_ANK1, PATIL_LIVER_CANCER, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, GOBP_PROTEIN_MATURATION, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_REGULATION_OF_CATABOLIC_PROCESS, BLALOCK_ALZHEIMERS_DISEASE_UP, BILD_E2F3_ONCOGENIC_SIGNATURE

GO Biological Process (5): positive regulation of Notch signaling pathway (GO:0045747), regulation of membrane protein ectodomain proteolysis (GO:0051043), protein maturation (GO:0051604), protein localization to plasma membrane (GO:0072659), intracellular protein localization (GO:0008104)

GO Molecular Function (2): enzyme binding (GO:0019899), protein binding (GO:0005515)

GO Cellular Component (4): nucleoplasm (GO:0005654), endoplasmic reticulum lumen (GO:0005788), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
Notch signaling pathway	1
regulation of Notch signaling pathway	1
positive regulation of signal transduction	1
membrane protein ectodomain proteolysis	1
regulation of proteolysis	1
regulation of protein catabolic process	1
gene expression	1
protein metabolic process	1
protein localization to membrane	1
protein localization to cell periphery	1
macromolecule localization	1
protein binding	1
binding	1
nuclear lumen	1
endoplasmic reticulum	1
intracellular organelle lumen	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

808 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TSPAN5	ADAM10	O14672	871
TSPAN5	ERICH3	Q5RHP9	738
TSPAN5	TSPAN31	Q12999	567
TSPAN5	ITGB1	P05556	560
TSPAN5	TSPAN13	O95857	535
TSPAN5	CD9	P21926	467
TSPAN5	TSPAN32	Q96QS1	451
TSPAN5	TMEM14C	Q9P0S9	450
TSPAN5	STPG2	Q8N412	411
TSPAN5	EPHB1	P54762	397
TSPAN5	RPL28	P46779	386
TSPAN5	IGSF8	Q969P0	375
TSPAN5	SLCO2A1	Q92959	374
TSPAN5	PTGFRN	Q9P2B2	363
TSPAN5	ADAM17	P78536	359

IntAct

23 interactions, top by confidence:

A	B	Type	Score
TSPAN15	ADAM10	psi-mi:“MI:0914”(association)	0.840
TSPAN5	ADAM10	psi-mi:“MI:0914”(association)	0.800
ADAM10	TSPAN5	psi-mi:“MI:0915”(physical association)	0.800
TSPAN5	ADAM10	psi-mi:“MI:0915”(physical association)	0.800
ADAM10	TSPAN5	psi-mi:“MI:0403”(colocalization)	0.800
CD9	ADAM10	psi-mi:“MI:0914”(association)	0.750
CD151	ADAM10	psi-mi:“MI:0914”(association)	0.530
TSPAN5	SC5D	psi-mi:“MI:0914”(association)	0.530
ADAM10	TSPAN5	psi-mi:“MI:0915”(physical association)	0.400
CREB3	TSPAN5	psi-mi:“MI:0915”(physical association)	0.370
ADAM10	TSPAN9	psi-mi:“MI:0914”(association)	0.350
ITGA3	ADAM10	psi-mi:“MI:0914”(association)	0.350
TSPAN5	KLHL2	psi-mi:“MI:0914”(association)	0.350

BioGRID (166): ADAM10 (Affinity Capture-Western), TSPAN5 (Affinity Capture-Western), TMEM248 (Affinity Capture-MS), VKORC1L1 (Affinity Capture-MS), TMEM87A (Affinity Capture-MS), ALG8 (Affinity Capture-MS), GDPD1 (Affinity Capture-MS), THAP11 (Affinity Capture-MS), AGPAT4 (Affinity Capture-MS), AGPAT3 (Affinity Capture-MS), SLC27A2 (Affinity Capture-MS), SPCS2 (Affinity Capture-MS), KLHL2 (Affinity Capture-MS), TMEM186 (Affinity Capture-MS), SOAT1 (Affinity Capture-MS)

ESM2 similar proteins: C3VMW3, D3ZQJ0, O00501, O54942, O88551, O88552, O95471, O95500, O95832, P56745, P56746, P56747, P56748, P56750, P56856, P56857, P57739, P62079, P62080, Q0VCN0, Q17QJ5, Q2HJ22, Q2KIY2, Q3B7N4, Q3MHK4, Q4KL25, Q58DR6, Q5I0E5, Q5PPI7, Q5QT56, Q68VK5, Q6DHP1, Q6L708, Q765P1, Q8BXA6, Q8N6F1, Q8NG11, Q8QZY6, Q8TAF8, Q95KM6

Diamond homologs: A0A8M2B5N2, A0A8V0ZLT4, B0BM39, B3VSC2, B5X3I6, O14817, O60635, O60636, O75954, P11049, P19397, P24485, P30932, P35762, P40240, P62079, P62080, Q06AA5, Q17QJ5, Q22495, Q2KHY8, Q2KIS9, Q3T0S3, Q4R7W6, Q4V8E0, Q568Y5, Q58CY8, Q58DM3, Q5R9S6, Q5RAP3, Q5RC27, Q61451, Q68VK5, Q6AYR9, Q6DCQ3, Q6GMK6, Q80WR1, Q8BJU2, Q8QZY6, Q8R3G9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	1
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2234 predictions. Top by Δscore:

Variant	Effect	Δscore
4:98476183:TCTTA:T	donor_loss	1.0000
4:98476184:CTTAC:C	donor_loss	1.0000
4:98476186:TA:T	donor_loss	1.0000
4:98476187:A:AG	donor_loss	1.0000
4:98476302:CTTC:C	acceptor_gain	1.0000
4:98476306:C:CC	acceptor_gain	1.0000
4:98476309:C:CT	acceptor_gain	1.0000
4:98476311:C:CT	acceptor_gain	1.0000
4:98476312:A:T	acceptor_gain	1.0000
4:98476411:A:AC	donor_gain	1.0000
4:98476412:C:CC	donor_gain	1.0000
4:98476412:CTG:C	donor_gain	1.0000
4:98476412:CTGGT:C	donor_gain	1.0000
4:98476457:CTTC:C	acceptor_gain	1.0000
4:98476458:TTC:T	acceptor_gain	1.0000
4:98476461:C:CC	acceptor_gain	1.0000
4:98476464:G:C	acceptor_gain	1.0000
4:98476464:G:GC	acceptor_gain	1.0000
4:98478683:A:AC	donor_gain	1.0000
4:98478684:C:CC	donor_gain	1.0000
4:98478684:CTG:C	donor_gain	1.0000
4:98481998:AACTT:A	donor_loss	1.0000
4:98481999:ACTT:A	donor_loss	1.0000
4:98482000:CTT:C	donor_loss	1.0000
4:98482001:TTACA:T	donor_loss	1.0000
4:98482002:T:TG	donor_loss	1.0000
4:98482003:A:AC	donor_gain	1.0000
4:98482003:AC:A	donor_loss	1.0000
4:98482004:C:CC	donor_gain	1.0000
4:98482004:C:CT	donor_loss	1.0000

AlphaMissense

1788 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:98476438:C:G	C200S	1.000
4:98476439:A:T	C200S	1.000
4:98478701:C:G	C187S	1.000
4:98478702:A:T	C187S	1.000
4:98478703:G:C	C186W	1.000
4:98478704:C:G	C186S	1.000
4:98478704:C:T	C186Y	1.000
4:98478705:A:G	C186R	1.000
4:98478705:A:T	C186S	1.000
4:98478713:G:T	P183Q	1.000
4:98478757:G:C	F168L	1.000
4:98478757:G:T	F168L	1.000
4:98478759:A:G	F168L	1.000
4:98478766:A:C	N165K	1.000
4:98478766:A:T	N165K	1.000
4:98478775:C:A	W162C	1.000
4:98478775:C:G	W162C	1.000
4:98478776:C:G	W162S	1.000
4:98478777:A:G	W162R	1.000
4:98478777:A:T	W162R	1.000
4:98478797:C:T	G155E	1.000
4:98478798:C:A	G155W	1.000
4:98478799:A:C	C154W	1.000
4:98478800:C:T	C154Y	1.000
4:98478804:A:G	C153R	1.000
4:98486772:C:T	G82E	1.000
4:98476220:G:T	A237D	0.999
4:98476267:A:C	C221W	0.999
4:98476268:C:G	C221S	0.999
4:98476268:C:T	C221Y	0.999

dbSNP variants (sampled 300 via entrez): RS1000000966 (4:98627369 A>C), RS1000007692 (4:98579287 A>G), RS1000026033 (4:98605605 A>T), RS1000028380 (4:98489911 C>T), RS1000047421 (4:98573709 G>A), RS1000061963 (4:98658911 A>C), RS1000066983 (4:98610416 T>C), RS1000079768 (4:98471407 G>A), RS1000084797 (4:98518092 GACTT>G), RS10000857 (4:98554123 C>A), RS1000089283 (4:98533431 C>T), RS1000103386 (4:98489651 C>T), RS1000103504 (4:98579020 C>G,T), RS1000119246 (4:98616983 C>G), RS1000128440 (4:98484088 A>C,G)

Disease associations

OMIM: gene MIM:613136 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST003091_7	Depressive episodes in bipolar disorder	9.000000e-06
GCST003518_99	Daytime sleep phenotypes	8.000000e-06
GCST004886_1	Alcohol consumption	4.000000e-13
GCST007328_12	Alcohol consumption (drinks per week)	2.000000e-18
GCST007328_13	Alcohol consumption (drinks per week)	9.000000e-18
GCST007621_1	Sensation seeking	1.000000e-07
GCST008259_7	Alcohol use disorder	3.000000e-09
GCST011176_25	Stroke	4.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007704	depressive episode measurement
EFO:0007828	daytime rest measurement
EFO:0006946	behavioural disinhibition measurement
EFO:0009458	alcohol use disorder measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs11947402	Other	4	citalopram;escitalopram	Depressive Disorder

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs11947402	TSPAN5	4	-0.50	1	citalopram;escitalopram

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression, affects cotreatment, decreases expression	7
Benzo(a)pyrene	increases methylation, affects expression, decreases expression	5
sodium arsenite	affects methylation, affects cotreatment, increases abundance, increases expression, decreases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Air Pollutants	increases abundance, increases oxidation, affects expression, decreases expression, affects cotreatment	3
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression, decreases expression	3
Estradiol	increases reaction, affects expression, affects cotreatment, increases expression	3
bisphenol A	decreases expression, affects cotreatment, increases methylation	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
Vorinostat	affects cotreatment, decreases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance, affects expression	2
Tretinoin	decreases expression, increases expression	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
cupric chloride	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
licochalcone B	decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Calcitriol	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer